Sepsis Research Analysis
Q2 2025 sepsis research converged on precision endotyping, host–pathogen mechanistic checkpoints, and practical stewardship. A Cell human proteome atlas enabled organ-origin inference from plasma, while cross-species multi-omics unified early metabolite signals with mitochondrial dysfunction for presymptomatic detection. Mechanistic work mapped druggable pathways across cell death (endothelial ferroptosis, caspase-11 pyroptosis), neuroimmune-immunometabolic axes (DRD2–TLR4–ACOD1–PD-L1), and host
Summary
Q2 2025 sepsis research converged on precision endotyping, host–pathogen mechanistic checkpoints, and practical stewardship. A Cell human proteome atlas enabled organ-origin inference from plasma, while cross-species multi-omics unified early metabolite signals with mitochondrial dysfunction for presymptomatic detection. Mechanistic work mapped druggable pathways across cell death (endothelial ferroptosis, caspase-11 pyroptosis), neuroimmune-immunometabolic axes (DRD2–TLR4–ACOD1–PD-L1), and host–drug synergy that rescues colistin activity under physiologic conditions. Microbiome ecology revealed endotoxemia-driven pathogen blooms, suggesting host-directed prevention of secondary infections. Clinically, a neonatal RCT supported 7-day antibiotic courses in select cases, complementing a broader shift toward context-aware AST and metabolism-informed antibiotic potentiation.
Selected Articles
1. Human proteome distribution atlas for tissue-specific plasma proteome dynamics.
A mass-spectrometry atlas maps plasma proteins to their tissue and cell origins across 18 organs and major blood cell types, validating organ-enriched panels in clinical cohorts (including sepsis) and enabling organ-specific plasma signatures for precision diagnostics.
Impact: Provides a foundational, validated resource to infer organ origin from plasma, accelerating organ-specific sepsis phenotyping, monitoring, and trial enrichment.
Clinical Implications: Enables rational design of plasma panels (liver, kidney, endothelium) to refine diagnosis, track responses, and select organ-directed therapies in sepsis.
Key Findings
- Built a proteome atlas across 18 vascularized organs and major blood cell types.
- Validated organ-enriched plasma panels across six cohorts including sepsis.
- Enabled inference of organ-origin signals for precision diagnostics.
2. Sublethal systemic LPS in mice enables gut-luminal pathogens to bloom through oxygen species-mediated microbiota inhibition.
Physiologic endotoxemia triggered 100–10,000-fold blooms of facultative gut pathogens within 24 hours without enteropathy via TLR4-dependent luminal ROS, transiently halting fermentation and favoring oxidative respiration.
Impact: Explains rapid dysbiosis and opportunistic blooms in critical illness, nominating host-directed strategies to prevent gut-derived secondary infections.
Clinical Implications: Motivates interventions that limit luminal oxidative stress, modulate TLR4 signaling, or support fermentation to curb pathogen blooms and translocation.
Key Findings
- Systemic LPS induced large-scale blooms of gut pathogens within 24 hours.
- Blooms occurred without overt mucosal injury, indicating ecological shifts.
- Mechanism required TLR4-driven increases in luminal ROS that halted fermentation.
3. Low leucine levels in the blood enhance the pathogenicity of neonatal meningitis-causing Escherichia coli.
Low blood leucine represses an sRNA (NsrP) via Lrp, derepressing purD and activating de novo purine biosynthesis in NMEC to increase bacteremia and meningitis; intravenous leucine blocked the axis and reduced disease in models.
Impact: Reveals a nutrient-sensing sRNA–metabolic axis controlling virulence and demonstrates a non-antibiotic, testable intervention (IV leucine).
Clinical Implications: Supports evaluation of controlled leucine supplementation and targeting of the Lrp–sRNA–purine axis in high-risk neonates, pending safety and PK studies.
Key Findings
- Low leucine enhances NMEC pathogenicity in vivo.
- Leucine depletion suppresses NsrP via Lrp to activate purine biosynthesis.
- Genetic perturbations and IV leucine validate causality and therapeutic potential.
4. Colistin exerts potent activity against mcr+ Enterobacteriaceae via synergistic interactions with the host defense.
Under physiologic media and in fresh human blood ex vivo, colistin retained bactericidal activity against mcr-1+ Enterobacteriaceae via enhanced complement deposition and serum synergy, and was effective in a murine bacteremia model, challenging conventional AST conclusions.
Impact: Reveals that standard AST can miss clinically relevant host–drug synergies, reopening therapeutic options for select drug-resistant bacteremias.
Clinical Implications: Encourages physiologic-condition AST or context-aware interpretation (e.g., complement competence) and supports prospective evaluation of colistin in selected mcr-1+ bacteremias.
Key Findings
- Colistin killed mcr-1+ strains in bicarbonate-containing media despite conventional AST suggesting inactivity.
- Enhanced complement deposition and synergized with human serum; killed mcr-1+ strains in fresh human blood.
- Showed efficacy as monotherapy in a murine bacteremia model.
5. Extracellular vesicle-packaged GBP2 from macrophages aggravates sepsis-induced acute lung injury by promoting ferroptosis in pulmonary vascular endothelial cells.
Macrophage-derived EVs enrich GBP2, which binds OTUD5 to promote GPX4 ubiquitination and endothelial ferroptosis, disrupting the vascular barrier and worsening sepsis lung injury; Plantainoside D bound GBP2, blocked GBP2–OTUD5, reduced GPX4 ubiquitination, and mitigated injury in models.
Impact: Identifies a druggable EV-mediated GBP2–OTUD5–GPX4 axis driving endothelial ferroptosis in sepsis lung injury, with a lead compound to enable translation.
Clinical Implications: Positions GBP2 or the OTUD5–GPX4 checkpoint as targets; EV-GBP2 may serve as a biomarker of endothelial injury; next steps include PK/tox studies and early-phase trials.
Key Findings
- Macrophage EVs induce endothelial ferroptosis and barrier disruption in sepsis models.
- GBP2 binds OTUD5 to promote GPX4 ubiquitination and ferroptosis.
- Plantainoside D disrupts GBP2–OTUD5 and attenuates lung injury.
6. Multi-Omics and -Organ Insights into Energy Metabolic Adaptations in Early Sepsis Onset.
Cross-species integration of presymptomatic human serum metabolomics/lipidomics with mouse single-nucleus RNA-seq identified serine and aminoadipic acid as discriminators of uncomplicated infection vs sepsis and revealed tissue-independent downregulation of mitochondrial energy genes.
Impact: Bridges human biomarker discovery with mechanistic validation, advancing early sepsis detection and nominating mitochondrial bioenergetics as a therapeutic node.
Clinical Implications: Serine-centered metabolite panels could support perioperative/ED risk stratification after validation; mitochondrial pathways warrant therapeutic exploration.
Key Findings
- Serine and aminoadipic acid discriminate infection from sepsis presymptomatically.
- Mitochondrial energy genes are downregulated across tissues early in sepsis.
- Serine-dependent shifts link systemic metabolites to organ bioenergetics.
7. GL-V9 inhibits Caspase-11 activation-induced pyroptosis by suppressing ALOX12-mediated lipid peroxidation to alleviate sepsis.
In murine sepsis and macrophage models, GL‑V9 inhibited ALOX12-mediated lipid peroxidation upstream of caspase-11 activation, reducing pyroptosis, tissue injury, cytokines, and mortality; Alox12 loss abrogated added benefit, supporting target specificity.
Impact: Nominates a druggable lipid-peroxidation checkpoint with in vivo survival benefit, advancing mechanism-based sepsis therapeutics.
Clinical Implications: Prioritize safety, PK/PD, and large-animal validation of ALOX12 inhibitors and evaluate infection-control tradeoffs before human trials.
Key Findings
- GL‑V9 reduced tissue injury, inflammatory cytokines, and mortality in CLP sepsis.
- Suppressed caspase‑11–dependent pyroptosis by inhibiting ALOX12-mediated lipid peroxidation.
- Genetic loss of Alox12 eliminated incremental benefit, confirming target engagement.
8. A neuroimmune pathway drives bacterial infection.
A dopamine–DRD2–TLR4–ACOD1 complex modulates ACOD1 transcription and PD-L1–mediated immunosuppression; dopaminergic agonism improved survival in murine sepsis and axis dysregulation correlated with human severity.
Impact: Defines a druggable neuroimmune–immunometabolic axis with in vivo efficacy and human relevance, opening translational avenues.
Clinical Implications: Supports biomarker development for DRD2–TLR4–ACOD1–PD-L1 and exploratory trials of dopaminergic agonists as adjunctive therapy.
Key Findings
- Dopamine via DRD2 modulates TLR4 signaling and suppresses LPS-induced ACOD1.
- ACOD1 upregulates PD-L1, promoting immunosuppression.
- Pramipexole improved survival; antagonism worsened outcomes in mice.
9. Seven-day versus 14-day antibiotic course for culture-proven neonatal sepsis: a multicentre randomised non-inferiority trial in a low and middle-income country.
In neonates (BW ≥1000 g) achieving clinical remission by day 7, a 7-day antibiotic course was non-inferior to 14 days for relapse within 21 days and shortened hospital stay by 4 days; outcomes were masked.
Impact: Practice-shaping evidence supporting shorter antibiotic duration in a defined neonatal subgroup with clear stewardship and resource implications.
Clinical Implications: Consider a 7-day course for improving, culture-proven neonatal sepsis (BW ≥1000 g, remission by day 7) with appropriate follow-up and local epidemiology alignment.
Key Findings
- Seven-day therapy non-inferior to 14 days for relapse within 21 days.
- Median hospital stay reduced by 4 days in the 7-day arm.
- Masked outcome assessment enhanced validity.
10. Innate Immune Activation Is a Strong Suppressor of CCL22 and Impedes Regulatory T Cell-Dendritic Cell Interaction.
Across in vitro, mouse models, and human samples, TLR/RLH/STING activation markedly suppresses dendritic-cell CCL22, reducing Treg–DC clustering; sepsis patients show decreased serum CCL22, suggesting timing cues for immunomodulation.
Impact: Defines an innate activation–mediated CCL22 suppression mechanism that weakens Treg support, guiding biomarker- and timing-based immunotherapy in sepsis.
Clinical Implications: CCL22 may identify an early proinflammatory window with reduced Treg support, informing timing and endpoints for immunomodulatory trials.
Key Findings
- Innate pathways (TLR/RLH/STING) robustly suppress CCL22 in dendritic cells.
- Reduced CCL22 decreases Treg–DC clustering; reproduced in infection models.
- Sepsis patients exhibit lower serum CCL22 than controls.